logo
logo

Leinco Technologies Receives Growth Equity Investment From Ampersand Capital Partners

Nov 17, 2021•over 3 years ago
St. Louis

Description

Leinco Technologies, a specialty manufacturer of life science reagents used in drug discovery research and in vitro diagnostics applications, today announced a majority recapitalization of the company by Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the life sciences and healthcare sectors. Ampersand's investment will be used to support the company's worldwide growth initiatives, including expanding manufacturing production capacity, broadening scientific capabilities and product offerings, and further developing the company's commercial and geographic presence.

Company Information

Company

Leinco Technologies

Location

St. Louis, Missouri, United States

About

Established in 1992, Leinco Technologies is a specialty manufacturer of early discovery research products, including antibodies, recombinant proteins, ELISA kits, and other life sciences products. Additionally, the company offers a full suite of custom development and manufacturing services and serves leading drug discovery and in vitro diagnostic companies around the world. Headquartered outside of St. Louis, Missouri, Leinco operates out of a 27,000 square foot facility with significant laboratory space to service all customer and regulatory requirements. Additional information about Leinco is available at www.leinco.com.